Phillip J. Koo, MD, presented “Advances in Imaging: a Radiologist’s Perspective” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.

How to cite: Koo, Phillip J. Advances in Imaging: a Radiologist’s Perspective” August 10th, 2020. Accessed Dec 2020.


Phillip J. Koo, MD, Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center, discusses current applications and potential future uses of PSMA PET/CT for imaging and treating prostate cancer. Dr. Koo notes that data from studies like ProPSMA clearly show that PSMA PET/CT is the most accurate and best diagnostic test available for prostate cancer. Access remains a problem however, as 68Ga-PSMA-11 is only currently available at two institutions in the United States. This will hopefully change soon, as companies are working to make cold kits for 68Ga-PSMA-11 widely available as well as to develop alternative imaging agents. As its availability increases, many questions remain about how PSMA PET/CT’s imaging capabilities can aid in treatment of metastatic and oligometastatic disease, and Dr. Koo concludes his discussion by observing that researchers have only just scratched the surface of PSMA’s value.

For more on imaging for prostate cancer, visit our learning center.

About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Koo presented this lecture during this year’s virtual conference in August 2020.